Business
CHANGE OF NAME
ANGLE plc announced that its application to change its name to CelLBxHealth plc has been registered. Effective October 29, 2025, at 8:00 a.m., the company's TIDM will change to CLBX on the London Stock Exchange, while its ISIN and SEDOL will remain unchanged. The company's website address will also change to CelLBxHealth.com, with AIM Rule 26 information accessible on the "Investors" section of the angleplc.com website from the same time. Shareholders' rights remain unaffected, and existing share certificates remain valid. Disclaimer*
About this update from Cellbxhealth Plc
29 October 2025 ANGLE plc ("the Company") Change of Name Further to the announcement on 8 October 2025, ANGLE plc announces that the application to change the name of the Company to CelLBxHealth plc has now been registered at Companies House. Accordingly, the Company's change of name and change of TIDM to CLBX will be effective on the London Stock Exchange plc from 8.00 a.m. on 29 October 2025. The Company's ISIN and SEDOL remain unchanged. In conjunction with the name change, the Company's website address will change to CelLBxHealth.com. All information required by AIM Rule 26 will be located on the "Investors" section of the angleplc.com website with effect from 8.00 a.m. on 29 October 2025. Shareholders' rights are unaffected by the change and existing share certificates should be retained and remain valid. For further information: CelLBxHealth +44 (0) 1483 343434 Dr Jan Groen, Executive Chairman Peter Collins, Interim CEO [email protected] Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper/ Hamza Munshi (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) +44 (0) 20 7220 0500 FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 Notes for editors About CelLBxHealth plc CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis including whole-cell imaging, proteomic profiling and full genomic workflows. Commercial activities focus on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development. The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from the Company's GLP certified UK laboratory, providing bespoke clinical-trial support and assay development.